Evidence map›Paper›PMID 40280196›Full record

ArticleThe American journal of cardiology2025

CHA

Mohammad Al Mouslmani, Mohamad Alhoda Alahmad, Zafer Akman, Raiza Rossi, Mufti Rahman, Michael G Nanna

Abstract read
In one paragraph

Article in The American journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  4. Article
  5. Left Atrial Appendage Occlusion in Cancer-Associated Atrial Fibrillation: Who, When, and How to Manage Antithrombotic Therapy.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammad Al MouslmaniDepartment of Hospital Medicine, Yale New Haven Hospital, New Haven, Connecticut.
Mohamad Alhoda AlahmadDepartment of Hospital Medicine, University of Kansas Medical Center, Kansas City, Kansas.
Zafer AkmanDepartment of Medicine, Yale New Haven Hospital, New Haven, Connecticut.
Raiza RossiDepartment of Medicine, Yale New Haven Hospital, New Haven, Connecticut.
Mufti RahmanDepartment of Hospital Medicine, Yale New Haven Hospital, New Haven, Connecticut; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
Michael G NannaSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut. Electronic address: Michael.nanna@yale.edu.

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Estimating the treatment effect of cardiovascular medications to modify the risk for future cognitive decline in older adultsK76AG088428 · NIA · YALE UNIVERSITY · PI Michael Nanna · 2024 to 2026
$729k
NIA NIH HHS K76 AG088428NIA NIH HHS P30 AG021342
6 · The paper itself

Abstract

The CHA

Indexed as

Atrial FibrillationNeoplasmsStrokeAgedAged, 80 and overAnticoagulantsCross-Sectional StudiesFemaleHospitalizationHumansMaleMiddle AgedRisk AssessmentRisk FactorsUnited StatesAnticoagulantsacute cerebrovascular accidentatrial fibrillation/fluttermalignancynationwide readmissions databasestroke

Identifiers

PMID40280196
PMCPMC13055880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.